
Cyclo Therapeutics Inc
NASDAQ:CYTH

Intrinsic Value
The intrinsic value of one
CYTH
stock under the Base Case scenario is
641.3
USD.
Compared to the current market price of 99 USD,
Cyclo Therapeutics Inc
is
Undervalued by 85%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Cyclo Therapeutics Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Cyclo Therapeutics Inc
Balance Sheet Decomposition
Cyclo Therapeutics Inc
Current Assets | 3.3m |
Cash & Short-Term Investments | 928k |
Receivables | 187.7k |
Other Current Assets | 2.1m |
Non-Current Assets | 2m |
PP&E | 46.6k |
Other Non-Current Assets | 2m |
Free Cash Flow Analysis
Cyclo Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Cyclo Therapeutics Inc
Revenue
|
870.7k
USD
|
Cost of Revenue
|
-76.2k
USD
|
Gross Profit
|
794.5k
USD
|
Operating Expenses
|
-25.5m
USD
|
Operating Income
|
-24.7m
USD
|
Other Expenses
|
-122.8k
USD
|
Net Income
|
-24.8m
USD
|
CYTH Profitability Score
Profitability Due Diligence
Cyclo Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

Score
Cyclo Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
CYTH Solvency Score
Solvency Due Diligence
Cyclo Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Score
Cyclo Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYTH Price Targets Summary
Cyclo Therapeutics Inc
Dividends
Current shareholder yield for CYTH is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CYTH
stock under the Base Case scenario is
641.3
USD.
Compared to the current market price of 99 USD,
Cyclo Therapeutics Inc
is
Undervalued by 85%.